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Summary 
Multiple sulfatase deficiency (MSD) is a lysosomal stor- 
age disorder characterized by a decreased activity of 
all known sulfatases. The deficiency of sulfatases was 
proposed to result from the lack of a co- or posttransla- 
tional modification that is common to all sulfatases 
and required for their catalytic activity. Structural anal- 
ysis of two catalytically active sulfatases revealed that 
a cysteine residue that is predicted from the cDNA se- 
quence and conserved among all known sulfatases is 
replaced by a 2-amino-3-oxopropionic acid residue, 
while in sulfatases derived from MSD cells, this cys- 
teine residue is retained. It is proposed that the co- or 
posttranslational conversion of a cysteine to 2-amino- 
3-oxopropionic acid is required for generating catalyti- 
cally active sulfatases and that deficiency of this pro- 
tein modification is the cause of MSD. 
Introduction 
Sulfate esters occur in a wide spectrum of biological com- 
pounds ranging from glycosaminoglycans and glycolipids 
to hydroxysteroids. They are hydrolyzed by a group of 
sulfatases that are distinguished by a high substrate speci- 
ficity. The sulfatases are members of an evolutionarily 
highly conserved gene family with substantial sequence 
homology among sulfatases of bacterial (Murooka et al., 
1990), lower eukaryotic (Sasaki et al., 1988; Yang et al., 
1989; de Hostos et al., 1989; Hallmann and Sumper, 
1994), and human (Yen et al., 1987; Robertson et al., 1988; 
Stein et al., 1989a, 1989b; Peters et al., 1990; Schuchman 
et al., 1990; Wilson et al., 1990; Tomatsu et al., 1991) 
origins. 
Of the nine human different sulfatases that have been 
characterized biochemically, eight are found in lysosomes, 
while steroid sulfatase is a membrane-bound microsomal 
enzyme. The biological significance of these sulfatases is 
emphasized by seven distinct human inherited disorders 
that are caused by the deficiency of specific sulfatases 
(for reviews see Ballabio and Shapiro, 1995; Neufeld and 
Muenzer, 1995). in addition, a rare autosomal recessive 
disorder, multiple sulfatase deficiency (MSD), is known in 
*The first two authors contributed equally to this work. 
which the activities of all known sulfatases are severely 
decreased. The clinical phenotype of MSD combines fea- 
tures of metachromatic leukodystrophy (MLD) with that of 
mucopolysaccharidosis (MPS) as a result of the impaired 
lysosomal catabolism of sulfated glycolipids and giycos- 
aminoglycans. In addition, an ichthyosis can develop ow- 
ing to the deficiency of the microsomal steroid sulfatase 
(Kolodny and Fluharty, 1995). 
The primary defect in MSD is unknown. Complementa- 
tion studies with single sulfatase deficiency disorders have 
shown that the structural genes for sulfatases are not af- 
fected (Horwitz, 1979; Chang and Davidson, 1980; Fedde 
and Horwitz, 1984; Ballabio et al., 1985). Expression of 
sulfatase cDNAs in MSD fibroblasts yielded sulfatase poly- 
peptides with a severely diminished catalytic activity 
(Rommerskirch and von Figura, 1992). This has led to the 
proposal that the basic defect in MSD affects a co- or 
posttranslational modification of sulfatases that is required 
for their catalytic activity. 
We therefore searched for a protein modification that 
is present in catalytically active sulfatases and deficient 
in the inactive sulfatases from MSD. In this study we report 
the identification of a protein modification in the two sul- 
fatases arylsulfatase A (ASA) and arylsulfatase B (ASB). 
This modification leads to the conversion of a cysteine 
residue into a 2-amino-3-oxopropionic a id residue and is 
deficient in ASA and ASB from MSD cells. 
Results 
Identification of an ASA Peptide with 
an Unknown Modification 
Analysis of ASA from control and MSD fibroblasts by SDS- 
polyacrylamide gel electrophoresis (Rommerskirch and 
von Figura, 1992) or isoelectric focusing (data not shown) 
failed to reveal any apparent differences that would point 
to a modification that distinguishes ASA from control cells 
and MSD cells. To facilitate the detection of a modification 
that has only subtle effects on molecular mass, we di- 
gested ASA with trypsin prior to mass determination. For 
this purpose, ASA precursors were isolated from secre- 
tions of BHK cells overexpressing human ASA (Chao et 
al., 1990) and were subjected to reductive carboxymethyl- 
ation in 6 M guanidinium hydrochloride to allow digestion 
with trypsin. The tryptic peptides were separated by re- 
versed-phase high pressure liquid chromatography (RP- 
H PLC) (Figure 1) and characterized by mass spectrometry 
and N-terminal sequencing. 
Tryptic digestion of ASA is predicted to yield 28 peptides. 
The peptides that were sequenced after separation by RP- 
HPLC accounted for 478 of the 489 residues of the precur- 
sor form of ASA. The missing 11 residues are predicted 
to reside in one dipeptide and three tripeptides. The 
masses of these di- and tripeptides were detected in the 
flowthrough fraction of the HPLC run. For all sequenced 
peptides, the observed and predicted masses were in per- 
fect agreement except for three peptides. Of these three 
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Figure 1. Separation by RP-HPLC of Tryptic Peptides from ASA 
The positions of peptide 2 (carboxymethylated form with a mass of 
1788 Da) and peptide 2* (modified form with a mass of 1714 Da) and 
the gradient from 0% to 900/o acetonitrile (broken line) are indicated. 
peptides, two contained N-glycosylation sites. After degly- 
cosylation with endoglycosidase H, their masses agreed 
with the predicted values, indicating that N-glycosylation 
fully accounted for the mass deviation. The only peptide 
with an unexplained mass deviation was peptide 2, which 
comprises residues 59-73 of ASA and which had a mass 
of 74 Da less than predicted. Interestingly, in all prepara- 
tions of ASA, a form of peptide 2 was recovered that had 
the predicted mass and accounted in different prepara- 
tions for 10%-40% of peptide 2. The two forms of peptide 
2 were separated by RP-HPLC (Figure 1). We reasoned 
that the major form of peptide 2 carries a modification that 
is missing in the minor form. This putatively modified form 
of peptide 2 was designated as peptide 2*. 
2-Amino-3-Oxopropionic Acid Replaces the 
Predicted Cys-69 in Peptide 2* 
Only the first ten residues of the 15-mer peptide 2* could 
be identified by direct sequencing. In cycles 11-15 (pre- 
dicted sequence, CTPSR), no signal was obtained (Figure 
2A). The presence of residues 12-15 (TPSR) could be 
demonstrated by amino acid analysis after strong acid 
hydrolysis. To verify the presence of Cys-69 (position 1 1 
in peptide 2"), we metabolically abeled cells with [35S]cys- 
teine. [35S]ASA was purified, and tryptic peptides were 
prepared. ASA contains 15 cysteine residues that are dis- 
tributed among seven tryptic peptides. The tryptic pep- 
tides containing cysteine residues 1 and 3-15 were recov- 
ered labeled to specific activity of 270-550 dpm/pmol 
cysteine (Figure 3). Peptide 2 is predicted to contain the 
second cysteine residue of ASA. Only the minor form of 
peptide 2 was radiolabeled, while its major form, the modi- 
fied peptide 2*, was not labeled (Figure 3). This indicated 
that the modification of peptide 2" was associated with a 
loss of the sulfur group of Cys-69. 
A critical information about the nature of the modification 
of Cys-69 was provided by tandem mass spectrometry. 
When peptide 2* was embedded in a glycerol matrix for 
tandem mass spectrometry, itwas desorbed as an adduct 
with glycerol. Analysis of the fragmentation products re- 
vealed that only fragments containing residue 11 (Cys-69) 
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Figure 2. Sequencing of ASA Peptide 2* and ASB Peptide 3C* 
Sequencing of ASA peptide 2* (A-C) and of ASB peptide 3C* (D-F) 
before (A and D) and after eduction with NaBH4 (B and E) or [SH]NaBH4 
(C and F). In (A), (B), (D), and (F), the amount of phenylthiohydantoine 
amino acid released in each cycle is given, and in (C) and (F), the 
radioactivity level is given. 
behaved as glycerol adducts (data not shown). The forma- 
tion of glycerol adducts points to the presence of an alde- 
hyde function in position 11 of peptide 2* (Dever et al., 
1989). The presence of a reducible aldehyde function in 
peptide 2* was confirmed in two ways. Treatment with 
NaBH4 led to an increase of the mass by -2  Da, from 
1714.4 to 1716.2 (Figures 4A and 4B). When peptide 2* 
was embedded in p-nitroaniline, a product of 1835.1 Da 
was desorbed that represents the Schiffs base formed 
between peptide 2* and p-nitroaniline (Figure 4C). 
The observed mass of 1714.4 Da of peptide 2* would 
conform to the predicted mass if the thiol group of cysteine 
was replaced by an aldehyde function. This would corre- 
spond to the replacement of the cysteine by a 2-amino-3- 
oxopropionic acid residue. If so, reduction of peptide 2* 
should convert residue 69 into the respective alcohol, 
which is serine. Indeed, when peptide 2* was reduced 
with NaBH4 and then subjected to amino acid sequencing, 
a signal for serine was observed in cycle 11, and in the 
following cycles (12-15), signals for the predicted residues 
were obtained (see Figure 2B). When peptide 2* was re- 
duced with [3H]NaBH4 and subjected to radiosequencing, 
the bulk of incorporated radioactivity was recovered in cy- 
cle 11 (see Figure 2C). The presence of a 2-amino-3- 
oxopropionic acid residue explains the interruption of Ed- 
man degradation in cycle 11, since the aldehyde function 
is predicted to interfere with the formation of the anUinothi- 
azolinone amino acid derivative during Edman degrada- 
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Figure 3. Separation by RP-HPLC of Tryptic Peptides from [~S]ASA 
[~S]ASA from BHK cells metabolically abeled with [~S]cysteine was 
mixed with unlabeled ASA prior to reductive carboxymethylation and 
digestion with trypsin. The gradient from 0% to 90% acetonitrile (bro- 
ken line) and the positions of the two forms of peptide 2 and of the 
tryptic peptides containing cysteine residues are indicated. The 15 
cysteine residues were numbered from 1 (N-terminal) to 15 (C-ter- 
minal). The minor form of the peptide containing Cys-9 (residues 378- 
439) represents a truncated form of the peptide due to proteolytic 
processing of ASA between residues 426 and 430 (Fujii et al., 1992). 
tion. We conclude from these results that peptide 2* con- 
tains a 2-amino-3-0xopropionic acid residue instead of the 
predicted Cys-69. 
Cys-69 of ASA Is Conserved among All Known 
EukaryoUc Sulfatases 
If the modification of Cys-69 to 2-amino-3-oxopropionic 
acid is considered as a candidate for the defect in MSD, 
Cys-69 and its modification should be conserved among all 
sulfatases. The available cDNA sequences of six human 
sulfatases indicate an identity of 20%-35% and similarity 
of 40%-60% among these enzymes (Wilson et al., 1990; 
Peters et al., 1990; Tomatsu et al., 1991). The homology 
extends over the entire sequence, but is highest in the 
N-terminal region. Among the areas of highest identity is 
the hexapeptide LN-C-X-P-S-R, where X carries a hy- 
droxyl or thiol group in five of six sulfatases (Figure 5). 
The cysteine in this hexapeptide corresponds to Cys-69 
in ASA. Even in the four sulfatases known from lower eu- 
karyotes (sea urchin and algae), this hexapeptide is con- 
served as V-C-T/C-P-S-R (Sasaki et al., 1988; Yang et 
al., 1989; de Hostos et al., 1989; Hallmann and Sumper, 
1994). 
2-Amino-3-Oxopropionic Acid in ASB 
ASB was analyzed for the presence of 2-amino-3- 
oxopropionic acid by a slightly different approach. ASB 
was directly reduced with [3H]NaBH4 in the presence of 
6 M guanidinium hydrochloride and then subjected to re- 
ductive carboxymethylation, tryptic digestion, and peptide 
separation by RP-HPLC. Incorporation of radioactivity was 
restricted to a single fraction (Figure 6). After rechromato- 
graphy, the labeled peptide could be identified as a modi- 
fied form of ASB peptide 3, designated as peptide 3*, 
which contains residues 69-95. The predicted cysteine 
residue 91 in peptide 3* is homologous to Cys-69 in ASA. 
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Figure 4. Mass Spectrometry ofASA Peptide 2* 
ASA peptide 2* was analyzed before (A) and after reduction with 
NaBH4 (B) or embedding in p-nitroaniline (C). 
If residue 91 is 2-amino-3-oxopropionic a id or (after re- 
duction) serine, the predicted masses are 2869.2 and 
2871.2 Da. The observed mass of peptide 3* was 2869 
Da, indicating that the predicted Cys-91 is indeed replaced 
in ASB by 2-amino-3-oxopropionic a id and that only the 
nonreduced form of peptide 3* was detected by mass 
spectrometry. 
For further analysis, peptide 3" was digested with endo- 
proteinase AspN to release the 13-mer peptide 3C* con- 
taining residues 83-95. The 13-mer peptide 3C* could be 
separated by RP-HPLC into two forms. The radioactivity 
was associated with only one of the two forms (inset in 
Figure 7). The masses of the radioactive and the nonradio- 
active form were 1541 and 1539 Da, respectively. These 
values agree with the masses predicted for the serine 
(1541.6 Da)-containing and 2-amino-3-oxopropionic a id 
(1539.6 Da)-containing forms of peptide 3C*, suggesting 
that reduction of ASB had been only partial. Radio- 
sequencing of peptide 3C* released the bulk of radioactiv- 
ity in cycle 9 (see Figure 2F), demonstrating that the reduc- 
ible group in ASB was associated with residue 91. Peptide 
3C* was also isolated from nonreduced ASB. Sequencing 
of this peptide was blocked in cycle 9. After treatment of 
ASB peptide 3C* with NaBH4, sequencing yielded a signal 
for serine in cycle 9 and, in the following four cycles, the 
signals for T, P, S, and R (see Figures 2D and 2E). It should 
be noted that in contrast with ASA, in which a fraction of 
peptide 2 was recovered in the nonmodified form con- 
taining the predicted Cys-69, only the modified form of 
ASB peptide 3 containing 2-amino-3-oxopropionic a id 
was recovered in tryptic digests of ASB. 
The tryptic peptides of ASB analyzed by sequencing 
and mass spectrometry covered 471 of 496 residues of 
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Figure 5. Homology among Human Sulfatases 
the ASB precursor. Except for peptide 3* and the five 
peptides containing the six predicted N-glycosylation 
sites, the observed and the predicted masses of the pep- 
tides were identical. The mass deviations of the five pep- 
tides carrying N-glycosylation sites varied between +860 
and +1500 Da and are attributed to the presence of 
N-linked oligosaccharides. Thus, the only detectable mod- 
ification in ASA and ASB apart from N-glycosylation was 
the modification of a conserved cysteine residue to 
2-amino-3-oxopropionic a id. 
2-Amino-3-Oxopropionic Acid Is Deficient in ASA 
and ASB from MSD Fibroblasts 
To examine sulfatases synthesized by MSD cells for the 
modification of the conserved cysteine, ASA and ASB 
were purified from MSD fibroblasts that overexpressed 
inactive ASA or ASB polypeptides after retroviral gene 
transfer. As controls, ASA and ASB were expressed in 
fibroblasts with a deficiency of ASA (MLD) or ASB (Maro- 
teaux-Lamy syndrome, also known as M PS type Vl). After 
infection with recombinant sulfatase-encoding retrovi- 
ruses, the MLD and MPS type VI fibroblasts synthesize 
catalytically active ASA or ASB (Rommerskirch and von 
Figura, 1992). 
To demonstrate the presence or absence of Cys-69 in 
ASA from MSD or MLD fibroblasts, we purified ASA from 
these cells. ASA was reacted with [14C]iodoacetic acid to 
[14C]carboxymethylate the free sulfhydryl groups. The 
[~4C]carboxymethylated ASA was then subjected to reduc- 
tive carboxymethylation, tryptic digestion, and separation 
by RP-HPLC. In ASA from MSD fibroblasts, the three pep- 
tides containing the cysteine residues 38, 69, and 414 
were labeled with 14C (Figure 7A). The amount of radioac- 
tivity associated with the peptide containing Cys-69 was 
139% and 116o/0 of that associated with peptides con- 
taining Cys-38 and Cys-414, respectively. The different 
amounts of radioactivity associated with the three peptides 
is assumed to be due to different recovery rates of the 
peptides. We conclude from these results that in ASA from 
MSD fibroblasts, of the 15 cysteine residues, only three, 
including Cys-69, expose a thiol group and that the re- 
maining 12 cysteine residues are disulfide bonded. 
When ASA from MLD fibroblasts was analyzed, signifi- 
cantly less radioactivity was associated with the Cys-69- 
containing peptide 2 (Figure 7B). When compared with 
the peptides containing Cys-38 or Cys-414, the amount 
of radioactivity associated with the peptide 2 was 34%. 
This is -3 -  to 4-fold lower than in ASA from MSD fibro- 
blasts. We conclude from these results that in ASA from 
MSD cells, Cys-69 is accessible to iodoacetic acid, while 
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Figure 6. Separation by RP-HPLC of Tryptic Peptides from [3H]ASB 
ASB was reduced with [3H]NaBH4 prior to reductive carboxymethyla- 
tion and digestion with trypsin. The position of the reduced [3H]peptide 
3* and the gradient from 0% to 55% acetonitrile (broken line) are 
indicated. The inset shows the separation by RP-HPLC of ASB peptide 
3C*, which was obtained by digestion of [3H]peptide 3* with endopro- 
teinase AspN. 
in ASA from MLD cells, the bulk of Cys-69 ( -70%) is 
nonaccessible. The latter is ascribed to its conversion to 
2-amino-3-oxopropionic a id. 
For ASB from MSD and MPS type VI fibroblasts, we 
could obtain direct evidence for the presence of cysteine 
or 2-amino-3-oxopropionic a id in position 91. ASB was 
subjected to reductive carboxymethylation, trypsin diges- 
tion, and RP-HPLC either prior to or after reduction with 
[3H]NaBH4. When ASB peptide 3 was obtained from MSD 
cells, it had a mass of 2944.1 Da that was not affected 
by embedding with p-nitroaniline. This corresponds to the 
mass predicted (2944.2 Da) for peptide 3 with a carboxy- 
methylated Cys-91. In contrast, ASB peptide 3 obtained 
from MPS type VI cells had a mass of 2868.1 Da, which 
corresponds to the mass predicted for the modified pep- 
tide 3* with a 2-amino-3-oxopropionic acid residue in posi- 
tion 91 (2869.2 Da). After embedding in p-nitroaniline, the 
mass increased to 2990.8 Da, which corresponds to that 
of the Schiff's base of peptide 3 with p-nitroaniline (2989.2 
Da). The presence of reducible groups in ASB from MPS 
type VI fibroblasts was also apparent when ASB was re- 
duced with [3H]NaBH4 prior to tryptic digestion. The bulk 
of radioactivity was recovered in the fraction containing 
peptide 3* (Figure 7D). Interestingly, when ASB from MSD 
fibroblasts was treated in an identical manner, a small 
amount of radioactivity was recovered in the fraction con- 
taining ASB peptide 3* (Figure 7C). This indicates that in 
MSD fibroblasts as well, a small fraction ( -  20%) of ASB, 
which escaped detection by mass spectrometry, carries 
a modified residue 91. All together these results demon- 
strate that the modification of a conserved cysteine to 
2-amino-3-oxopropionic acid in sulfatases is severely defi- 
cient in MSD. 
Discussion 
A Novel Co- or Posttranslational Modification 
in Sulfatases 
We have identified in the two sulfatases ASA and ASB 
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Figure 7. Separation by RP-HPLC of Tryptic Peptides from [14C]Car- 
boxymethyiated ASA and [SH]ASB 
(A and B) ASA from MSD fibroblasts (A) or MLD fibroblasts (B) was 
treated with [14C]iodoacetic a id prior to reductive carboxymethylation 
and digestion with trypsin. The gradient from 0% to 90% acetonitrile 
(broken line) and the position of the ASA peptides containing Cys-38, 
Cys-69, or Cys-414 are indicated. 
(C and D) ASB from MSD fibroblasts (C) or MPS type VI fibroblasts 
(D) was treated with [SH]NaBH4 prior to reductive carboxymethylation 
and digestion with trypsin. The gradient from 0% to 90% acetonitrile 
(broken line) and the position of ASB peptide 3* (arrow) are indicated. 
2-amino-3-oxopropionic a id residues at positions where 
the cDNA sequences predict a cysteine residue. Three 
observations upport the notion that the 2-amino-3-oxo- 
propionic acid residues are generated by a co- or a post- 
translational modification of cysteine residues and are not 
directly incorporated uring translation. In ASA isolated 
from BHK cells that overproduce ASA, a fraction of ASA 
contains the predicted cysteine. This fits with the view that 
cysteine is incorporated uring translation and modified 
co- or posttranslationally to 2-amino-3-oxopropionic a id 
by a mechanism that is saturable. Catalysis of this modifi- 
cation by a saturable mechanism and requirement of the 
modification for catalytic activity (see below) can explain 
why overexpression of a sulfatase is associated with a 
severe decrease of the activities of endogenous ulfatases 
(Anson et al., 1993). Additional evidence for the co- or post- 
translational generation of 2-amino-3-oxopropionic a id 
comes from the observation that ASA and ASB from MSD 
fibroblasts lack the modified residues and instead retain 
the predicted cysteines (see below). 
The 2-Amino-3-Oxopropionic Residue Is Part 
of a Conserved Sequence 
The cysteine residue that becomes modified in ASA and 
ASB is conserved among the known six human sulfatases 
and the four sulfatases from lower eukaryotes. Moreover, 
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Figure 8. Conversion of Cysteine to 2-Amino-3-Oxopropionic Acid 
Shown is a hypothetical mechanism for the conversion of cysteine to 
2-amino-3-oxopropionic acid in sulfatases. The subsequent reaction 
of the aldehyde group with functional groups of amino acid side chains 
or of low molecular mass components i indicated. 
this cysteine is embedded in a highly homologous se- 
quence of 13 residues, nine of which are identical in at 
least five of the six human sulfatases (Figure 5). This con- 
sensus sequence may act as a colinear recognition motif 
for the machinery that is modifying the cysteine. Formally, 
the conversion of a protein-bound cysteine to 2-amino-3- 
oxopropionic acid can be conceived as the result of a two- 
step reaction (Figure 8), the first step being a dehydroge- 
nase reaction yielding a thioaldehyde as intermediate, 
followed by a hydrolysis step yielding the aldehyde and 
hydrogen sulfide. Since the secreted precursor forms of 
lysosomal sulfatases such as ASA or ASB are catalytically 
active, the modifying reactions must occur within the se- 
cretory route. Steroidsulfatase has been isolated from en- 
doplasmic reticulum in an active form (Ballabio and Sha- 
piro, 1995), indicating that the modification occurs in the 
endoplasmic reticulum as an early posttranslational or 
even cotranslational event. 
Deficiency of 2-Amino-3-Oxopropionic Acid 
in Sulfatases from MSD 
The search for a modification in sulfatases was prompted 
by the hypothesis that generation of catalytically active 
sulfatase depends on a co- or posttranslational modifica- 
tion and that this modification is deficient in MSD. We 
therefore examined sulfatases from MSD cells for the 
presence of 2-amino-3-oxopropionic a id. To obtain suffi- 
cient quantities of ASA and ASB, we had to overexpress 
the sulfatases in MSD fibroblasts using recombinant re- 
troviruses, For comparison, ASA and ASB were overex- 
pressed in fibroblasts that were capable of synthesizing 
active sulfatases, but lacked endogenous ASA or ASB 
owing the mutations in the respective sulfatase genes. In 
ASA from MSD fibroblasts, the presence of Cys-69 rather 
that 2-amino-3-oxopropionic a id could be demonstrated 
only indirectly by the accessibility of residue 69 to carboxy- 
methylation. Interestingly, also in ASA from controls, a 
fraction ( -30%)  of residue 69 was accessible to carboxy- 
methylation, suggesting that under the conditions of over- 
expression (and possibly also at a normal expression 
level), part of the newly synthesized ASA escapes the co- 
or posttranslational modification in fibroblasts. 
The presence of Cys-91 in ASB from MSD fibroblasts 
and its substitution by 2-amino-3-oxopropionic acid in ASB 
from control fibroblasts could be verified directly by mass 
spectrometry and reduction with [SH]NaBH4. By reduction 
with [SH]NaBH4, we could demonstrate that, even in ASB 
from MSD cells, - 20% of Cys-91 is modified. This agrees 
with the observation that in MSD fibroblasts the activities 
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of sulfatases are not completely deficient (Steckel et al., 
1985). Even in fibroblasts from patients with the severe 
form of MSD, which were used in this study and in which 
the residual activity of sulfatases is usually below 5%, it 
may reach 150/0, namely for ASB (Rommerskirch and von 
Figura, 1992). We conclude from the analysis of ASA and 
ASB from control and MSD fibroblasts that the conversion 
of cysteine to 2-amino-3-oxopropionic a id is catalyzed by 
a saturable mechanism that is severely deficient but not 
absent in MSD. 
Role of 2-Amino-3-Oxopropionic Acid 
for Hydrolysis of Sulfate Esters 
Comparatively little is known about the mechanism of sul- 
fate ester bond hydrolysis by sulfatases. A SO4-sulfatase 
complex has been proposed as a catalytic intermediate 
(Roy, 1978). This may be related to the observation that 
under certain conditions ASA is inactivated uring hydroly- 
sis of p-nitrocatechol sulfate and that this inactivation is 
associated with covalent and stoichiometric incorporation 
of sulfate (Waheed and van Ellen, 1979, 1980). 
The correlation between generation of catalytically ac- 
tive sulfatases and  conversion of a cysteine residue to 
2-amino-3-0xopropionic acid suggests that the latter may 
be of importance for the catalytic mechanism. It is, how- 
ever, questionable whether in sulfatases the aldehyde 
group of the 2-amino-3-0xopropionic acid residue is free. 
In native sulfatases, the aldehyde function may be stabi- 
lized as an enol or linked to an amino or a hydroxyl function 
forming a Schiff's base or a hemiacetal. The amino or 
hydroxyl function may be part of the sulfatase polypeptide 
chain or of a low molecular weight cofactor. If the cofactor 
is a ketone, it could also form an aldol. In fact, preliminary 
experiments argue against the presence of a free alde- 
hyde group in sulfatases. When native ASA and ASB were 
treated with [3H]NaBH,, they failed to incorporate radioac- 
tivity (T. S., un published data). Reduction of the 2-amino-3- 
oxopropionic acid residue required the denaturation of the 
sulfatases by guanidinium hydrochloride. This suggests 
that in native sulfatases the 2-amino-3-oxopropionic acid 
residue is stabilized as enol or is linked to one of the func- 
tional groups indicated above and that unfolding is re- 
quired to shift the equilibrium to the free aldehyde. 
Experimental Procedures 
Purification of Sulfatases 
Sulfatases were purified from secretions of BHK cells, which coex- 
pressed human ASA (Chao et al., 1990) or human ASB (Peters et 
al., 1990) together with the human Mr 46,000 mannose 6-phosphate 
receptor, and from cell extracts (50-100 mg of cell protein) of fibro- 
blasts from patients with MSD (cell line Mo), MLD (cell line La), or 
MPS type VI (cell line Ya) infected with recombinant retroviruses con- 
raining the cDNAs of human ASA or ASB (for cell lines and recombinant 
retroviruses, see Rommerskirch and von Figura, 1992). Where indi- 
cated, [~S]ASA (0.78 rnCi; 0.62 mCi/mrnol) was purified from medium, 
and cell extracts were prepared of BHK cells metabolically labeled 
with [~S]cysteine, as described previously (Somrnerlade t al., 1994). 
ASA was purified by affinity chromatography as described pre- 
viously (Somrnerlade t al,, 1994). ASB was immunopurified using 
an affinity column derivatized with the monoclonal antibody ASB 4.1 
(Gibson et al., 1987) and the conditions described for purification 
of ASA. 
Reductive Carboxymethylation, Tryptic Digestion, 
and Separation of Tryptic Peptides 
Purified ASA and ASB (10-100 ~g) were freeze-dried and dissolved 
in 6 M guanidinium hydrochloride, 400 mM Tris-HCI (pH 8.6), and 10 
mM EDTA. Dithiothreitol was added to a final concentration of 50 raM, 
mixed, and incubated for 1 hr at 50°C in an oxygen-free atmosphere. 
Following reduction, 2 M iodoacetic acid, adjusted to pH 8.6 with am- 
monium hydroxide, was added to a final concentration of 150 rnM and 
incubated for 30 rain at room temperature in darkness. To complete 
the reaction, a second cycle of reduction and carboxymethylation with 
65 mM dithiothreitol and 122 mM iodoacetic acid (final concentration) 
followed. The sulfatases were then desalted on an HPLC system 
(SMART; Pharrnacia) using a Sephadex G25 column (fast-desalting 
PC 3.2/10; Pharrnacia) equilibrated with 50 rnM ammonium acetate 
and 10% acetonitrile OH 8.6). The desalted sulfatases were digested 
with lO/o (w/w) (ASA) or 2% (w/w) (ASB) trypsin for 16 hr at 37°C. 
Tryptic peptides were separated by RP-HPLC using a 220 mm x 
2.1 mm C8 column (Aquapore RP300; BAI) or, for the separation of 
peptides from [~S]ASA, a 250 mm x 4.6 mm C18 column (Widepore 
RP18; Baker) equilibrated with 0.10/o trifluoracetic acid in H20 and 
eluted with an increasing acetonitrile concentration (0.9% acetonitrile 
per minute) and a flow rate of 0.3 rnl per minute, Eluted peptides were 
collected by manual fractionation and subjected to mass spectrometry, 
N-terminal sequencing, or cleavage with endoglycosidase H (see be- 
low) or endoproteinase AspN as described previously (Somrnerlade 
et al., 1994). 
Digestion with Endoglucosidase H 
Purified tryptic glycopeptides from ASA or ASB (-300 pmol) were 
dried, redissolved in 50 ill of 50 rnM sodium acetate (pH 5.5), and 
digested with 2 rnU of endoglycosidase H (Boehringer Mannheim) 
for 2 hr at 37°C. After a second incubation for 2 hr with 2 mU of 
endoglycosidase H, peptides were purified by RP-HPLC and analyzed 
by mass spectrometry. 
Reduction with pH]NaBH4 
Lyophilized ASB, ASB peptide 3C*, or ASA peptide 2* (50-300 prnol) 
was dissolved in 20 ~1 of 4 M guanidinium hydrochloride, 10 mM EDTA, 
25 mM Tris (pH 8.6) and incubated for 1 hr at 37°C. For reduction, 
NaBH4 or [3H]NaBH, (11.2 Ci/rnnrnol; Arnersham Corporation) from a 
75 mM stock solution in 10 rnM NaOH was added to a final concentra- 
tion of 2.6 rnM. After incubation for 1 hr at room temperature, excess 
of NaBH, was destroyed by addition of 1 vol of 50 mM acetic acid and 
incubation for 30 min at room temperature. Following reduction, ASA 
peptide 2* and ASB peptide 3C* were purified by RP-HPLC as de- 
scribed and subjected to mass spectrometry analysis and sequencing. 
Reduced ASB was subjected to reductive carboxymethylation, tryptic 
digestion, and peptide separation by RP-HPLC as described above. 
The HPLC fractions were analyzed by mass spectrometry, N-terminal 
sequencing, or liquid scintillation counting. The [3H]peptide 3* from 
ASB from normal cells was rechrornatographed by RP-HPLC using 
an acetonitrile gradient of 0.5% per minute and digested with endopro- 
teinase AspN as described previously (Sommerlade t al., 1994). After 
purification by RP-HPLC, the [3H]peptide 3C* was subjected to mass 
spectrometry analysis and radiosequencing. 
[14C]Carboxymethylation of ASA from MSD and MLD Cells 
ASA purified from MSD or MLD fibroblasts was lyophilized, dissolved 
in 4 M guanidinium hydrochloride, 10 mM EDTA, and 25 mM Tris (pH 
8.6), and incubated for 1 hr at 37°C. For carboxymethylation f free 
sulfhydryl groups, 10 mM [14C]iodoacetic a id (53 mCi/mmol) was 
added to a final concentration of 0.5 mM. Following an incubation for 
1 hr at room temperature in darkness, the [14C]ASA was subjected to 
reductive carboxymethylation, tryptic digestion, and peptide separa- 
tion by RP-HPLC as described above. The HPLC fractions were ana- 
lyzed by mass spectrometry and scintillation counting. 
Matrix-Assisted Laser Desorption Ionization 
Mass Spectrometry 
We dried - 1 ~.1 of indole-2-carbonic a id or 2.5-dihydroxybenzoic a id 
(10 rng/ml in acetone) on the sample slide to produce a thin matrix 
film. On this film, 0.5 pl of the HPLC fractions were dried and subjected 
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to mass spectrometry analysis. Alternatively, equal amounts of sample 
and matrix were mixed and dried on the sample slide. The samples 
were analyzed in a VISION 2000 (Finnigan MAT) or a MALDI III (Shi- 
madzu) mass spectrometer. As mass standards for calibration, bovine 
insulin (M,, 5733.5) and a synthetic peptide (M,, 1979.1) were used. 
Mass data were evaluated using the personal computer program 
GPMAW (Lighthouse Data). To demonstrate the presence of an alde- 
hyde group in ASA peptide 2 * or ASB peptide 3C *, we used p-nitroaniline 
as a matrix, which forms a Schiff's base with aldehydes. 
Amino Acid Sequencing 
Sequence analysis of the tryptic peptides was performed as described 
previously (Sommerlade t al., 1994). For radiosequencing of [3H]ASA 
peptide 2* or ASB peptide 3C*, the cleaved anilinothiazolinone amino 
acids were collected in a fraction collector and radioactivity was quan- 
tified. 
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